Episode #151. Cracking the Hypertension Code: One Patch, No Limits ,with Jay Heimsoth, National Director of Sales at Biobeat

A life-saving technology finally solves the biggest flaw in hypertension care, and it’s as simple as wearing a patch.

In this episode, Jay Heimsoth, National Director of Sales at Biobeat, explains that Biobeat has launched the first FDA-cleared cuffless 24-hour blood pressure monitor, addressing a massive unmet need for hypertension management where 74% of 120 million U.S. patients remain uncontrolled. Unlike traditional cuff-based monitors, Biobeat’s wearable patch improves comfort, compliance, and data quality while integrating features like digital diaries for actionable insights. He highlights strong clinical validation, including a Mayo Clinic study demonstrating near-beat-by-beat agreement with arterial line measurements. Looking ahead, Jay’s priorities include building Biobeat’s culture, developing a strong team, and creating an organization people want to join and stay in.

Tune in to hear how Biobeat’s cuffless BP monitor is reshaping diagnostics and redefining what’s possible in cardiovascular care!

About Jay Heimsoth:

Jay Heimsoth is the National Director of Sales at Biobeat, leading the launch of the first FDA-cleared cuffless 24-hour blood pressure monitor. Passionate about addressing hypertension, the leading risk factor for cardiovascular disease, Jay focuses on bringing disruptive technology to a massive, underserved patient population while improving physician decision-making through actionable data. He is also dedicated to building strong, people-first teams and a culture where employees can grow, thrive, and feel inspired to be part of a shared mission.

Things You’ll Learn:

• Hypertension remains massively undertreated, with 74% of 120 million U.S. patients still uncontrolled.

• Biobeat has launched the first FDA-cleared cuffless 24-hour blood pressure monitor, solving the comfort, compliance, and data-gap problems of traditional cuff-based devices.

• The wearable chest patch provides continuous, highly accurate data, validated in 26 clinical studies, including Mayo Clinic research showing 96–99% agreement with arterial line measurements.

• New digital features like an integrated patient diary give physicians actionable insights by linking symptoms, medications, and activities to blood pressure changes.

• There is strong reimbursement and clinical guideline support for 24-hour monitoring, making the market ready for disruption.

• Biobeat focuses specifically on BP and heart rate, filling a technology gap not addressed by existing cardiac monitoring companies.

• Jay’s leadership priorities center on building a strong, people-first culture, where accountability, growth, and genuine embodiment of company values drive success.

• Biobeat aims to become a place where people want to join and stay, emphasizing mentorship, internal promotion, and supporting employees in reaching their career goals.

   

  Resources:

• Connect with and follow Jay Heimsoth on LinkedIn.

• Follow Biobeat on LinkedIn and explore their website!

   

  For more information and ways to increase risk awareness and safety, visit us at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.censinet.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.